52090-25-2

Upstream product

• 24078-21-5 methyl 3-methyl-4-nitrobenzoate 

Downstream Products

• 1085940-85-7 {3-[[1-(2-bromo-5-oxo-6-thiophen-2-ylmethyl-5,6-dihydro-1H-1,6,8-triaza-cyclopenta[b]naphthalen-7-yl)-2-methyl-propyl]-(4-methyl-benzoyl)-amino]-propyl}-carbamic acid tert-butyl ester 
• 1085938-15-3 C₃₀H₃₂BrN₅O₂S 

Relevant academic research and scientific papers

Insights into the myosin II inhibitory potency of A-ring-modified (S)-blebbistatin analogs

Myosin II is an interesting target for therapeutic intervention, as it is involved in a large number of motility-based diseases. (S)-Blebbistatin is a known micromolar inhibitor of this protein. A new series of (S)-blebbistatin derivatives with a modified

KINESIN INHIBITORS

This invention relates to the compounds of formula (I) shown below. Each variable in formula (I) is defined in the specification. These compounds can be used to treat a kinesin Eg5 protein-mediated disorder.